Cell Source, Inc.
CLCSDrugs in Pipeline
32
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Gemcitabine
Pancreatic Ductal Adenocarcinoma
NiCord® (omidubicel)
Hematological Malignancies
JointStem
Osteoarthritis, Knee
Adoptive Cellular Therapy
Cytomegalovirus Infection
omidubicel
Hematological Malignancies
Activated T lymphocyte(Immuncell-LC)
Glioblastoma
Immuncell-LC
Carcinoma, Hepatocellular
mesenchymal stem cells
Lung Injury
GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
Acute Myelogenous Leukemia
CMV-specific T-cells, single infusion following single positive CMV PCR result
Cytomegalovirus Infection
CV787 (CG7870)
Prostate Cancer
Therapeutic Cellular Vaccine, GM-CSF Producing
Multiple Myeloma
GXNPC1
Chronic Stroke
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Prostate Cancer
AstroStem
Alzheimer Disease
GIC-102
Advanced Solid Tumors
Super DC Vaccine
Solid Tumor Cancer
Cytovir-ADV
ADV Infection Post Allo-HSCT
single dose of CNCT19
Relapsed or Refractory Acute Lymphoblastic Leukemia
NTCELL Implantation
Parkinson's Disease
Activated T lymphocyte
Pancreatic Cancer
Allogeneic adult mesenchymal bone marrow stem cells
Ischemic Stroke
Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Retinitis Pigmentosa
Synvisc-One
Osteoarthritis, Knee
CG8123
Lung Cancer
CG 8020 and CG 2505
Metastatic Pancreatic Cancer
SCG101
Hepatitis B Virus Related Hepatocellular Carcinoma
MG4101
Hepatocellular Carcinoma
Tendoncel
Lateral Epicondylitis
[²¹²Pb]Pb-ADVC001
Prostate Cancer
mesenchymal stem cell
AIDS
NiCord
Sickle Cell Disease & Thalassemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gemcitabine | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
NiCord® (omidubicel) | Phase 3 | Hematological Malignancies | - | - |
JointStem | Phase 3 | Osteoarthritis, Knee | - | - |
Adoptive Cellular Therapy | Phase 3 | Cytomegalovirus Infection | - | - |
omidubicel | Phase 3 | Hematological Malignancies | - | - |
Activated T lymphocyte(Immuncell-LC) | Phase 3 | Glioblastoma | - | - |
Immuncell-LC | Phase 3 | Carcinoma, Hepatocellular | - | - |
mesenchymal stem cells | Phase 2 | Lung Injury | - | - |
GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing) | Phase 2 | Acute Myelogenous Leukemia | - | - |
CMV-specific T-cells, single infusion following single positive CMV PCR result | Phase 2 | Cytomegalovirus Infection | - | - |
CV787 (CG7870) | Phase 2 | Prostate Cancer | - | - |
Therapeutic Cellular Vaccine, GM-CSF Producing | Phase 2 | Multiple Myeloma | - | - |
GXNPC1 | Phase 2 | Chronic Stroke | - | - |
Immunotherapy allogeneic GM-CSF secreting cellular vaccine | Phase 2 | Prostate Cancer | - | - |
AstroStem | Phase 2 | Alzheimer Disease | - | - |
GIC-102 | Phase 2 | Advanced Solid Tumors | - | - |
Super DC Vaccine | Phase 2 | Solid Tumor Cancer | - | - |
Cytovir-ADV | Phase 2 | ADV Infection Post Allo-HSCT | - | - |
single dose of CNCT19 | Phase 2 | Relapsed or Refractory Acute Lymphoblastic Leukemia | - | - |
NTCELL Implantation | Phase 2 | Parkinson's Disease | - | - |
Activated T lymphocyte | Phase 2 | Pancreatic Cancer | - | - |
Allogeneic adult mesenchymal bone marrow stem cells | Phase 2 | Ischemic Stroke | - | - |
Umbilical Cord Mesenchymal Stem Cell (UC-MSC) | Phase 2 | Retinitis Pigmentosa | - | - |
Synvisc-One | Phase 2 | Osteoarthritis, Knee | - | - |
CG8123 | Phase 2 | Lung Cancer | - | - |
CG 8020 and CG 2505 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
SCG101 | Phase 2 | Hepatitis B Virus Related Hepatocellular Carcinoma | - | - |
MG4101 | Phase 2 | Hepatocellular Carcinoma | - | - |
Tendoncel | Phase 2 | Lateral Epicondylitis | - | - |
[²¹²Pb]Pb-ADVC001 | Phase 2 | Prostate Cancer | - | - |
mesenchymal stem cell | Phase 2 | AIDS | - | - |
NiCord | Phase 2 | Sickle Cell Disease & Thalassemia | - | - |